Actively Recruiting
Evaluation of HM15275 Compared to Placebo for 36 Weeks in Adults with Type 2 Diabetes Mellitus Using Weekly Injections
Led by Hanmi Pharmaceutical Company Limited · Updated on 2026-10-19
180
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, safety, and tolerability of HM15275 in adults with type 2 diabetes mellitus T2DM who have inadequate blood sugar control. This Phase 2 clinical trial involves participants aged 18 to 75 years with specific body mass indexes and HbA1c levels between 7.0% and 10.0%. The study aims to understand how HM15275 affects blood sugar control over 36 weeks compared to placebo. Participants are randomly assigned to one of four groups in a double-blind manner, receiving either HM15275 or a placebo through weekly subcutaneous injections over 36 weeks. The study includes a 4-week screening period before treatment and a 4-week safety follow-up period after treatment ends. Randomization considers initial HbA1c levels and metformin use to balance participant characteristics. Throughout the study, participants will undergo regular assessments to monitor changes in glycated hemoglobin HbA1c, adverse events, and other health measures. Researchers will evaluate the percentage of participants reaching target HbA1c levels while closely observing safety and tolerability. The total participation duration is approximately 44 weeks, including screening, treatment, and follow-up.
CONDITIONS
Brief Title
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
Research Team
P
Pureun Nam
H
Hyeonho Choi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here